Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

Noam Pondé; Dominique Agbor‑Tarh; Lissandra Dal Lago; Larissa A. Korde; Florentine Hilbers; Christian Jackisch; Olena Werner; Richard D. Gelber; Aminah Jatoi; Amylou C. Dueck; Alvaro Moreno‑Aspitia; Christos Sotiriou; Evandro de Azambuja; Martine Piccart

doi:10.1007/s10549-021-06409-y

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

Noam Pondé, Dominique Agbor‑Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D. Gelber, Aminah Jatoi, Amylou C. Dueck, Alvaro Moreno‑Aspitia, Christos Sotiriou, Evandro de Azambuja, Martine Piccart

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here. The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.

Original language	English (US)
Pages (from-to)	225
Number of pages	1
Journal	Breast Cancer Research and Treatment
Volume	191
Issue number	1
DOIs	https://doi.org/10.1007/s10549-021-06409-y
State	Published - Jan 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-021-06409-y

Fingerprint

Dive into the research topics of 'Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)'. Together they form a unique fingerprint.

Cite this

Pondé, N., Agbor‑Tarh, D., Dal Lago, L., Korde, L. A., Hilbers, F., Jackisch, C., Werner, O., Gelber, R. D., Jatoi, A., Dueck, A. C., Moreno‑Aspitia, A., Sotiriou, C., de Azambuja, E., & Piccart, M. (2022). Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9). Breast Cancer Research and Treatment, 191(1), 225. https://doi.org/10.1007/s10549-021-06409-y

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9). / Pondé, Noam; Agbor‑Tarh, Dominique; Dal Lago, Lissandra et al.
In: Breast Cancer Research and Treatment, Vol. 191, No. 1, 01.2022, p. 225.

Research output: Contribution to journal › Comment/debate › peer-review

Pondé, N, Agbor‑Tarh, D, Dal Lago, L, Korde, LA, Hilbers, F, Jackisch, C, Werner, O, Gelber, RD, Jatoi, A , Dueck, AC , Moreno‑Aspitia, A, Sotiriou, C, de Azambuja, E & Piccart, M 2022, 'Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)', Breast Cancer Research and Treatment, vol. 191, no. 1, pp. 225. https://doi.org/10.1007/s10549-021-06409-y

Pondé N, Agbor‑Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C et al. Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9). Breast Cancer Research and Treatment. 2022 Jan;191(1):225. doi: 10.1007/s10549-021-06409-y

Pondé, Noam ; Agbor‑Tarh, Dominique ; Dal Lago, Lissandra et al. / Correction to : Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9). In: Breast Cancer Research and Treatment. 2022 ; Vol. 191, No. 1. pp. 225.

@article{e88d8f971f9b4f2f99504c69a841a085,

title = "Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)",

abstract = "In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here. The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.",

author = "Noam Pond{\'e} and Dominique Agbor‑Tarh and {Dal Lago}, Lissandra and Korde, {Larissa A.} and Florentine Hilbers and Christian Jackisch and Olena Werner and Gelber, {Richard D.} and Aminah Jatoi and Dueck, {Amylou C.} and Alvaro Moreno‑Aspitia and Christos Sotiriou and {de Azambuja}, Evandro and Martine Piccart",

note = "Funding Information: The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis. Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC, part of Springer Nature 2021.",

year = "2022",

month = jan,

doi = "10.1007/s10549-021-06409-y",

language = "English (US)",

volume = "191",

pages = "225",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

AU - Pondé, Noam

AU - Agbor‑Tarh, Dominique

AU - Dal Lago, Lissandra

AU - Korde, Larissa A.

AU - Hilbers, Florentine

AU - Jackisch, Christian

AU - Werner, Olena

AU - Gelber, Richard D.

AU - Jatoi, Aminah

AU - Dueck, Amylou C.

AU - Moreno‑Aspitia, Alvaro

AU - Sotiriou, Christos

AU - de Azambuja, Evandro

AU - Piccart, Martine

N1 - Funding Information: The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis. Publisher Copyright: © Springer Science+Business Media, LLC, part of Springer Nature 2021.

PY - 2022/1

Y1 - 2022/1

N2 - In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here. The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.

AB - In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here. The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.

UR - http://www.scopus.com/inward/record.url?scp=85116544965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116544965&partnerID=8YFLogxK

U2 - 10.1007/s10549-021-06409-y

DO - 10.1007/s10549-021-06409-y

M3 - Comment/debate

C2 - 34625860

AN - SCOPUS:85116544965

SN - 0167-6806

VL - 191

SP - 225

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this